论文部分内容阅读
目的:探讨Runx2和Galectin-3在脑胶质瘤中的表达、相互关系及二者与临床病理因素之间的关系。方法:SP免疫组织化学方法检测Runx2和Galectin-3在50例胶质瘤标本中的表达,同时取10例正常脑组织作为对照。结果:Runx2和Galectin-3在10例正常脑组织中不表达,在脑胶质瘤中的阳性表达率分别为:74%及58%;二者的表达与肿瘤组织学分级、肿瘤的复发及5年生存率有关,差异有显著统计学意义(P<0.05);而与患者年龄、肿瘤大小不相关(P>0.05);在脑胶质瘤中Galectin3的表达与Runx2的表达高度相关,且二者的表达呈正相关(r=0.627,P<0.05)。结论:Runx2、Galectin-3在脑胶质瘤中有表达,二者可能参与了胶质瘤的发生发展,对二者表达的检测对脑胶质瘤的治疗具有指导意义。
OBJECTIVE: To investigate the expression of Runx2 and Galectin-3 in glioma and their relationship with clinicopathological factors. Methods: SP immunohistochemistry was used to detect the expression of Runx2 and Galectin-3 in 50 glioma specimens, and 10 normal brain tissues were taken as control. Results: Runx2 and Galectin-3 were not expressed in 10 normal brain tissues. The positive expression rates of Runx2 and Galectin-3 in gliomas were 74% and 58%, respectively. The expressions of Runx2 and Galectin-3 were correlated with tumor histological grade, tumor recurrence and 5-year survival rate, the difference was statistically significant (P <0.05), but not with patient age and tumor size (P> 0.05). The expression of Galectin3 was highly correlated with Runx2 expression in gliomas The two expressions were positively correlated (r = 0.627, P <0.05). Conclusions: Runx2 and Galectin-3 are expressed in glioma, both of which may be involved in the development of glioma. The detection of Glx and Galectin-3 may play a guiding role in the treatment of glioma.